This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Prothipendyl is a neuroleptic agent indicated in the treatment of restlessness and agitation in patients with underlying psychiatric conditions.
- Generic Name
- Prothipendyl
- DrugBank Accession Number
- DB12958
- Background
Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Prothipendyl (DB12958)
- Weight
- Average: 285.41
Monoisotopic: 285.129968798 - Chemical Formula
- C16H19N3S
- Synonyms
- Prothipendyl
- Prothipendylum
- Protipendilo
- External IDs
- AY 56031
- D 206
- LG 206
- MH 05101
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Prothipendyl. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Prothipendyl. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Prothipendyl. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Prothipendyl. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Prothipendyl. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Prothipendyl. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Prothipendyl. Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Prothipendyl. Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Prothipendyl. Alverine The risk or severity of CNS depression can be increased when Alverine is combined with Prothipendyl. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Prothipendyl hydrochloride 7610629RVH 1225-65-6 CQJSAKJMCVSEGU-UHFFFAOYSA-N Prothipendyl hydrochloride monohydrate 9G1ILH80SA 70145-94-7 YATJECIBCQMRMY-UHFFFAOYSA-N - International/Other Brands
- Dominal / Tumovan
Categories
- ATC Codes
- N05AX07 — Prothipendyl
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Alkyldiarylamines
- Alternative Parents
- Diarylthioethers / Benzothiazines / Pyridines and derivatives / Imidolactams / Benzenoids / 1,4-thiazines / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Alkyldiarylamine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzothiazine / Diarylthioether / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam show 6 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5O6VWA87VA
- CAS number
- 303-69-5
- InChI Key
- JTTAUPUMOLRVRA-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H19N3S/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19/h3-5,7-10H,6,11-12H2,1-2H3
- IUPAC Name
- dimethyl(3-{9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaen-2-yl}propyl)amine
- SMILES
- CN(C)CCCN1C2=CC=CC=C2SC2=C1N=CC=C2
References
- General References
- DIMDI Drug Product Information: Dominal (prothipendyl hydrochloride) for oral use [Link]
- External Links
- PubChem Compound
- 14670
- PubChem Substance
- 347829098
- ChemSpider
- 14002
- 55244
- ChEBI
- 135182
- ChEMBL
- CHEMBL2111030
- ZINC
- ZINC000000001996
- Wikipedia
- Prothipendyl
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Anxiety Disorders / Dementia / Depression / Psychosomatic Disorders / Schizophrenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 50 mg/mL Tablet, coated Oral 40 MG Tablet, film coated Oral Tablet, film coated Oral 80 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.128 mg/mL ALOGPS logP 3.53 ALOGPS logP 3.31 Chemaxon logS -3.4 ALOGPS pKa (Strongest Basic) 9.2 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 19.37 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 87.11 m3·mol-1 Chemaxon Polarizability 32.44 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 21, 2016 01:35 / Updated at June 05, 2023 04:57